Recombinant Anti-RANK antibody [EPR4740(N)] (ab182158)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4740(N)] to RANK
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-RANK antibody [EPR4740(N)]
See all RANK primary antibodies -
Description
Rabbit monoclonal [EPR4740(N)] to RANK -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details
Unsuitable for: Flow Cyt -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: Human fetal liver, fetal thymus and adult adrenal gland and small intestine tissue lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Tissue culture supernatant -
Clonality
Monoclonal -
Clone number
EPR4740(N) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab182158 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 80 kDa (predicted molecular weight: 66 kDa).
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 80 kDa (predicted molecular weight: 66 kDa). |
Target
-
Function
Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. -
Tissue specificity
Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. -
Involvement in disease
Defects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early onset deafness and loss of dentition.
Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull.
Defects in TNFRSF11A are the cause of osteopetrosis autosomal recessive type 7 (OPTB7) [MIM:612301]; also called osteoclast-poor osteopetrosis with hypogammaglobulinemia. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTB7 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. OPTB7 is associated with hypogammaglobulinemia. -
Sequence similarities
Contains 4 TNFR-Cys repeats. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 8792 Human
- Omim: 603499 Human
- SwissProt: Q9Y6Q6 Human
- Unigene: 204044 Human
-
Alternative names
- CD 265 antibody
- CD265 antibody
- FEO antibody
see all
Images
-
All lanes : Anti-RANK antibody [EPR4740(N)] (ab182158) at 1/10000 dilution
Lane 1 : Human adrenal gland tissue lysate
Lane 2 : Human fetal liver tissue lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab136636) at 1/500 dilution
Predicted band size: 66 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted? -
All lanes : Anti-RANK antibody [EPR4740(N)] (ab182158) at 1/2000 dilution
Lane 1 : Human small intestine tissue lysate
Lane 2 : Human fetal thymus tissue lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab136636) at 1/500 dilution
Predicted band size: 66 kDa
Observed band size: 80 kDa why is the actual band size different from the predicted?
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (3)
ab182158 has been referenced in 3 publications.
- Yan B et al. Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression. Biomed Res Int 2020:2753414 (2020). PubMed: 32337233
- Fioramonti M et al. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. Sci Rep 8:4177 (2018). WB . PubMed: 29520051
- Tohyama R et al. Establishment of a xenograft model to explore the mechanism of bone destruction by human oral cancers and its application to analysis of role of RANKL. J Oral Pathol Med 45:356-64 (2016). WB ; Human . PubMed: 26859422